ÂÜÀòÂÒÂ×

Søren Møller is a business executive with a background in the pharmaceutical and medical industries. Søren is currently the managing partner of Novo Seed, a venture capital firm that is part of Novo Holdings. Prior to this, they were with AMRA Medical, a Swedish company that develops and markets MRI-based body composition analysis solutions. Before that, they were with Novo Holdings, a large Danish investment holding company, where they were a member of the board of directors.

Møller has also served on the boards of Forendo Pharma Ltd and NorthSea Therapeutics. Søren was with RSPR Pharma from September 2015 to November 2017. In December 2021, Forendo Pharma was acquired by Organon in a deal worth up to 954 million USD.

Søren Møller has an M.Sc. in molecular biology from the Technical University of Denmark and a field in marketing innovative technologies from Harvard Business School.

They are on a team with Charles Patten - Principal, Amit Kakar - Senior Partner, Head of Novo Holdings Asia, and Morten Beck Jørgensen - Managing Partner, Financial Investments. Søren Møller reports to Kasim Kutay, CEO. Some direct reports include Aleks Engel - Partner, Novo Seed, Morten Graugaard Døssing - Partner, Novo Seed, and Emmanuelle Coutanceau - Partner, Novo Seeds.